Transplant Conditioning

OTHER3 trials

Sponsors

Fred Hutchinson Cancer Center, National Cancer Institute (NCI), City of Hope Medical Center

Conditions

AIDS-Related Hodgkin LymphomaAIDS-Related Non-Hodgkin LymphomaAcute Lymphoblastic LeukemiaHIV InfectionRecurrent Classic Hodgkin LymphomaRecurrent Hodgkin LymphomaRecurrent Non-Hodgkin LymphomaRefractory Classic Hodgkin Lymphoma

Early Phase 1

Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia

RecruitingNCT06735690

City of Hope Medical CenterAcute Lymphoblastic Leukemia

Start: 2025-06-09End: 2029-03-07Target: 15Updated: 2025-11-12

Phase 1

Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

WithdrawnNCT02378922

Fred Hutchinson Cancer CenterAIDS-Related Hodgkin Lymphoma, AIDS-Related Non-Hodgkin Lymphoma, HIV Infection +2

Start: 2016-06-22End: 2019-06-15Updated: 2018-12-27

Phase 3

A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma

WithdrawnNCT05711628

National Cancer Institute (NCI)Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma

Start: 2023-08-10End: 2028-06-30Updated: 2024-03-20